+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07360743

Evaluating Anti-PD1 Monotherapy Based on PTI Biomarker in Advanced NSCLC Patients with High PD-L1 Expression

Led by UNICANCER · Updated on 2026-09-25

275

Participants Needed

4

Research Sites

173 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the use of anti-PD-1 monotherapy as a first-line treatment for advanced or metastatic non-small cell lung cancer NSCLC patients with high PD-L1 expression tumor proportion score >50%. This study addresses the challenge that while anti-PD-1 therapy offers durable responses, some patients experience rapid tumor growth called hyperprogressive disease HPD. The trial aims to validate a blood biomarker signature called the Pro-Tumoral Inflammation PTI score to predict which patients may benefit from immunotherapy alone, potentially avoiding chemotherapys toxic effects. Participants with advanced NSCLC and a PD-L1 TPS >50% will be assessed for their PTI score through blood tests. Those with a PTI score of zero, indicating low levels of specific inflammatory markers, will receive anti-PD-1 monotherapy with pembrolizumab or cemiplimab every three weeks via intravenous infusion. Patients with higher PTI scores will be monitored under standard treatment without receiving the study drug. Imaging and tumor assessments will be conducted regularly, including at baseline, weeks 6 and 12, and then according to routine care for up to 36 months. During the study, participants will provide fresh blood samples for immune profiling, and optional tumor biopsies may be collected at baseline and early treatment to evaluate immune response. Researchers will measure the rate of patients without early disease progression at 12 weeks as the primary outcome. Follow-up includes imaging scans and survival monitoring for up to three years. The trial is designed to refine treatment selection by identifying patients likely to benefit from immunotherapy alone, improving outcomes while minimizing unnecessary chemotherapy exposure.

CONDITIONS

Brief Title

Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

Research Team

P

Priyanka DEVI-MARULKAR, PhD, MBA

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here